MX2022006770A - Dispersiones solidas de bendamustina e infusion continua. - Google Patents

Dispersiones solidas de bendamustina e infusion continua.

Info

Publication number
MX2022006770A
MX2022006770A MX2022006770A MX2022006770A MX2022006770A MX 2022006770 A MX2022006770 A MX 2022006770A MX 2022006770 A MX2022006770 A MX 2022006770A MX 2022006770 A MX2022006770 A MX 2022006770A MX 2022006770 A MX2022006770 A MX 2022006770A
Authority
MX
Mexico
Prior art keywords
solid dispersions
continuous infusion
bendamustine
bendamustine hydrochloride
degradants
Prior art date
Application number
MX2022006770A
Other languages
English (en)
Inventor
Vasilios Voudouris
Original Assignee
Vasilios Voudouris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasilios Voudouris filed Critical Vasilios Voudouris
Publication of MX2022006770A publication Critical patent/MX2022006770A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden mostaza de nitrógeno, por ejemplo, clorhidrato de bendamustina, dispersiones sólidas sustancialmente libres de degradantes. También se proporcionan métodos para producir y administrar mostazas de nitrógeno y en particular dispersiones sólidas e clorhidrato de bendamustina sustancialmente libres de degradantes. Las composiciones farmacéuticas pueden ser usadas para cualquier enfermedad que es sensible al tratamiento con clorhidrato de bendamustina, tal como enfermedades neoplásicas.
MX2022006770A 2014-03-13 2016-08-30 Dispersiones solidas de bendamustina e infusion continua. MX2022006770A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461952624P 2014-03-13 2014-03-13

Publications (1)

Publication Number Publication Date
MX2022006770A true MX2022006770A (es) 2022-06-22

Family

ID=52684713

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016011236A MX2016011236A (es) 2014-03-13 2015-03-04 Dispersiones solidas de bendamustina e infusion continua.
MX2022006770A MX2022006770A (es) 2014-03-13 2016-08-30 Dispersiones solidas de bendamustina e infusion continua.
MX2021002633A MX2021002633A (es) 2014-03-13 2016-08-30 Dispersiones solidas de bendamustina e infusion continua.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016011236A MX2016011236A (es) 2014-03-13 2015-03-04 Dispersiones solidas de bendamustina e infusion continua.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002633A MX2021002633A (es) 2014-03-13 2016-08-30 Dispersiones solidas de bendamustina e infusion continua.

Country Status (9)

Country Link
US (5) US9320730B2 (es)
EP (1) EP3116481A1 (es)
JP (3) JP6883428B2 (es)
CN (2) CN115350155A (es)
AU (3) AU2015229842B2 (es)
CA (1) CA2941632C (es)
IL (1) IL247739A0 (es)
MX (3) MX2016011236A (es)
WO (1) WO2015138199A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016002502A (es) 2013-08-27 2017-02-28 Voudouris Vasilios Composiciones farmaceuticas de bendamustina.
CN110121338A (zh) * 2016-07-13 2019-08-13 武田药品工业株式会社 脾酪氨酸激酶抑制剂和其他治疗剂的组合
ES2928931T3 (es) 2018-03-29 2022-11-23 Project Pharmaceutics Gmbh Formulación farmacéutica líquida
CN108324691B (zh) * 2018-04-11 2019-03-08 健进制药有限公司 一种注射用卡莫司汀冻干制剂及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227374A (en) * 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
DE19757224A1 (de) * 1997-12-22 1999-07-01 Bayer Ag Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
CN101933923A (zh) * 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2006105399A1 (en) * 2005-03-31 2006-10-05 Bristol-Myers Squibb Company Methods for administering ixabepilone
CN101272769B (zh) * 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
EP2240172B1 (en) * 2007-12-21 2014-03-19 Novartis AG Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP2012502902A (ja) * 2008-09-17 2012-02-02 シージェイ チェルジェダン コーポレイション アデホビルジピボキシルの安定化した固体分散体及びその製造方法
WO2010036702A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
MX2011011109A (es) * 2009-04-28 2011-11-18 Cephalon Inc Formulaciones orales de bendamustina.
PL2528602T5 (pl) * 2010-01-28 2020-09-07 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20140142153A1 (en) 2011-01-25 2014-05-22 Dr. Reddy's Laboratories, Inc. Bendamustine formulations
WO2013102920A1 (en) * 2011-11-18 2013-07-11 Astron Research Limited Stable lyophilized formulation of bendamustine
US20130172271A1 (en) * 2012-01-04 2013-07-04 Cynthia Fragale Pharmaceutical Spray Drying
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
EP2811984B1 (en) * 2012-02-06 2015-08-26 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
EP2641592A1 (en) * 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
MX2016002502A (es) * 2013-08-27 2017-02-28 Voudouris Vasilios Composiciones farmaceuticas de bendamustina.

Also Published As

Publication number Publication date
JP6883428B2 (ja) 2021-06-09
JP2020055831A (ja) 2020-04-09
AU2015229842B2 (en) 2020-06-25
WO2015138199A1 (en) 2015-09-17
US9907752B2 (en) 2018-03-06
US20210346289A1 (en) 2021-11-11
US20160310422A1 (en) 2016-10-27
AU2020233707A1 (en) 2020-10-15
JP2022095923A (ja) 2022-06-28
US20230364017A1 (en) 2023-11-16
AU2015229842A1 (en) 2016-09-15
US20150258069A1 (en) 2015-09-17
CN115350155A (zh) 2022-11-18
MX2021002633A (es) 2021-05-12
MX2016011236A (es) 2017-04-06
US20180185279A1 (en) 2018-07-05
CA2941632A1 (en) 2015-09-17
JP2017507958A (ja) 2017-03-23
CN106102722A (zh) 2016-11-09
AU2022211893A1 (en) 2022-09-15
US9320730B2 (en) 2016-04-26
IL247739A0 (en) 2016-11-30
CA2941632C (en) 2023-10-24
EP3116481A1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
MY191574A (en) Pharmaceutical compositions comprising meloxicam
ECSP16075472A (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
IN2013MU03583A (es)
IN2013MU00711A (es)
EA201591758A1 (ru) Подкожное введение adamts13
MX2021002633A (es) Dispersiones solidas de bendamustina e infusion continua.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2016011706A (es) Formulaciones de progesterona.
MX2016002502A (es) Composiciones farmaceuticas de bendamustina.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
WO2014170769A3 (en) Bendamustine lyophilized pharmaceutical compositions
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
IN2013MU01510A (es)
IN2013MU03855A (es)
IN2014MU00667A (es)